ADA: AZ’s oral GLP-1 shows ‘competitive efficacy’ in phase 2, setting stage for pivotal program

When looking out across the competitive GLP-1 landscape, AstraZeneca might not be the first Big Pharma name that comes to With a pair of phase 2 readouts, AstraZeneca is positioning itself to potentially capture a portion of the oral GLP-1 market. Up next, its elecoglipron is heading into pivotal studies. Biotech Cell & Gene Therapy Clinical Data Venture Capital Deals Research Medtech Devices Diagnostics AI and Machine Learning CRO Special Reports Trending Biologics Clinical Development Ophthalmology Cell & Gene Therapy Drug Development Small Molecule Research & Development Fierce 50 Special Report Awards Gala Awards Outsourcing Awards Innovation Awards Resources…

Source: FierceBiotech